GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2006

Wyeth’s Renal Cell Carcinoma Drug Gets NDA Priority Review Status

  • The FDA granted priority review status to Wyeth Pharmaceuticals’ NDA related to its therapy against advanced renal cell carcinoma (RCC). Torisel™ (temsirolimus) is the first mTOR (mammalian target of rapamycin) inhibitor to be filed for approval for the treatment of a cancer, the company reports. It is an investigational drug that specifically inhibits the mTOR kinase, a protein that regulates cell proliferation, cell growth, and cell survival.

    The FDA previously granted fast-track designation and orphan drug status for investigational temsirolimus for the same indication.

    The application contains interim data from a three-arm, Phase III trial of 626 patients who had received no prior systemic therapy. Wyeth says the results showed that Torisel significantly increased overall survival by 49% in patients with advanced RCC compared with interferon-alpha, a treatment for advanced RCC.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?